All In Biotech

Drug Trial Radar · NCT02027701

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003

Last checked: Nov 19, 2026Latest source record: Oct 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

82

Actual

Start

Jul 30, 2014

Primary completion

Jul 10, 2017

Study completion Jul 10, 2017

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jan 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an extension study to the pivotal study IgPro20\_3003 (NCT01545076). The purpose of this extension study is to investigate the long-term treatment of CIDP with IgPro20, with regard to safety and efficacy. Subjects who have completed subcutaneous (SC) Week 25 or were successfully rescued from a CIDP relapse during the SC Treatment Period of pivotal study IgPro20\_3003 (NCT01545076) will have the option to receive open-label low-dose IgPro20 (0.2 g/kg bodyweight \[bw\]) weekly for up to 48 weeks. Subjects relapsing on low-dose IgPro20 will either return to high-dose IgPro20 (0.4 g/kg) immediately or be discontinued, depending on investigator's judgment. Subjects returning to high-dose IgPro20 will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment. If subjects do not successfully recover from CIDP relapse within 4 weeks, they will be withdrawn. The treatment duration will be up to 48 weeks, followed by a completion visit (week 49).

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions

  • IgPro20Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs) Per InfusionTime frame: Up to 49 weeks

Locations

33 sites in 11 countries. Site status is shown where the registry gives one.

  • Site Reference 8400181

    Birmingham, Alabama

  • Site Reference 8400167

    Los Angeles, California

  • Site Reference 8400166

    Kansas City, Kansas

  • Site Reference 8400169

    New York, New York

  • Site Reference 8400182

    Charlotte, North Carolina

  • Site Reference 0360017

    Woolloongabba, Queensland, Australia

  • Site Reference 0360011

    Fitzroy, Victoria, Australia

  • Site Reference 1240009

    Toronto, Ontario, Canada

  • Site Reference 1240007

    Greenfield Park, Quebec, Canada

  • Site Reference 2030009

    Hradec Králové, Czechia

  • Site Reference 2030002

    Hradec Králové, Czechia

  • Site Reference 2500022

    Nice, France

  • Site Reference 2760069

    Berlin, Germany

  • Site Reference 2760072

    Berlin, Germany

  • Site Reference 2760049

    Bochum, Germany

  • Site Reference 2760094

    Essen, Germany

  • Site Reference 2760054

    Hanover, Germany

  • Site Reference 2760055

    Leipzig, Germany

  • Site Reference 2760047

    Potsdam, Germany

  • Site Reference 2760039

    Würzburg, Germany

  • Site Reference 2760052

    Essen, North Rhine-Westphalia, Germany

  • Site Reference 3800031

    Milan, Italy

  • Site Reference 3920038

    Chiba, Japan

  • Site Reference 3920061

    Kanagawa, Japan

  • Site Reference 3920040

    Nagoya, Japan

  • Site Reference 3920065

    Tokyo, Japan

  • Site Reference 3920037

    Tokorozawa, Saitama, Japan

  • Site Reference 3920035

    Ube, Yamaguchi, Japan

  • Site Reference 5280001

    Amsterdam, Netherlands

  • Site Reference 7240011

    Barcelona, Spain

  • Site Reference 7240010

    Barcelona, Spain

  • Site Reference 8260019

    London, United Kingdom

  • Site Reference 8260032

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.